Co-occurring weight- and/or shape-motivated restriction in 5,747 adults with probable ARFID
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objective
According to DSM-5-TR, avoidant/restrictive food intake disorder (ARFID) cannot be diagnosed alongside anorexia nervosa (AN), bulimia nervosa (BN), or any other body image disturbance. This does not accurately reflect real-world symptomatology and recent research findings, indicating the potential need to revise DSM-5-TR Criteria. In this study, we investigated the co-occurrence of weight- and/or shape-motivated restriction (WSR) in a large sample of adults who screened positive for ARFID, thereby providing evidence to inform such changes.
Methods
The sample comprised 5,747 adults who consented to participate in the ARFID-Genes and Environment (ARFID-GEN) research study, screened positive for ARFID on the NIAS and PARDI-AR-Q, and completed the EDE-Q. Based on EDE-Q responses, participants were placed into four groups: groups one and two additionally screened positive for AN (ARFID-AN; n=147) or BN (ARFID-BN; n=193), group three also endorsed significant WSR without meeting AN or BN screening criteria (ARFID-WSR; n=2,097), and group four endorsed ARFID symptoms only (ARFID-nWSR; n=3,310). We used generalized linear models to test group differences on the NIAS, PARDI-AR-Q and EDE-Q.
Results
ARFID-nWSR showed lower scores than all other groups across most ARFID dimensions on the NIAS and PARDI-AR-Q, as well as lower odds of meeting DSM-5-TR Criteria A1 to A4 (i.e., weight loss; nutritional deficiencies; dependence on nutritional supplements; significant interference with psychosocial functioning) .
Discussion
These findings indicate the presence of a mixed phenotype with features of both ARFID and WSR that is associated with more severe ARFID symptomatology as measured by NIAS and PARDI-AR-Q in the general population. The current DSM-5-TR Criteria may not accurately capture complex real-world symptomatology in adults with probable ARFID, potentially precluding those with the most severe symptoms from receiving diagnoses that accurately reflect their clinical presentation and from accessing appropriate care.
